XML 64 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income (Loss) Before Income Taxes
The components of income (loss) before income taxes are as follows:
 Year Ended December 31, 
 202420232022
 $$$
U.S.201,516 117,446 67,744 
PRC(263,159)(315,852)(583,610)
Other(471,358)(627,430)(1,445,171)
Total(533,001)(825,836)(1,961,037)
Schedule of Current and Deferred Components of the Income Tax Expense (Benefit)
The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:
 Year Ended December 31, 
 202420232022
 $$$
Current tax expense (benefit)   
U.S.57,222 25,170 4,844 
PRC12,331 24,956 27,905 
Other16,225 5,059 6,547 
Total85,778 55,185 39,296 
Deferred tax expense (benefit)
U.S.23,556 — — 
PRC180 687 3,480 
Other2,271 — 
Total26,007 687 3,482 
Income tax expense (benefit)111,785 55,872 42,778 
Schedule of Reconciliation of the Statutory Tax Rate to Effective Income Tax Rate
The reconciliation of the statutory tax rate to our effective income tax rate is as follow:
 Year Ended December 31, 
 202420232022
 $$$
Loss before tax(533,001)(825,836)(1,961,037)
U.S. statutory tax rate21 %21 %21 %
Expected taxation at U.S. statutory tax rate(111,930)(173,426)(411,818)
Foreign and preferential tax rate differential93,741 144,310 209,384 
Non-deductible expenses1,130 19,134 29,223 
Stock compensation expenses53,446 32,581 33,872 
State tax expense (benefit)(7,988)(5,872)1,683 
Change in valuation allowance157,286 845,811 229,550 
Tax relief credits— (704,928)— 
Research tax credits and incentives(43,602)(64,343)(42,844)
Deductible research expenses(13,644)— — 
Tax on unremitted earnings23,743 — — 
Foreign-derived intangible income(40,397)(37,395)(6,272)
Taxation for the year111,785 55,872 42,778 
Effective tax rate(21.0)%(6.8)%(2.2)%
Schedule of Components of Deferred Tax Assets (Liabilities)
Significant components of deferred tax assets (liabilities) are as follows:
 Year Ended December 31,
 202420232022
 
Accruals and reserves121,549 106,708 97,896 
Net operating losses carryforward1,137,890 996,588 862,214 
Stock-based compensation38,397 26,687 19,700 
Research tax credits34,561 68,117 86,000 
Tax relief credits704,928 704,928 — 
Intangible asset amortization1,081,442 699,974 813,043 
Lease liability obligation11,882 7,893 10,348 
R&D and other capitalized costs277,061 164,190 63,156 
Total gross deferred tax assets3,407,710 2,775,085 1,952,357 
Less valuation allowance(3,403,505)(2,771,470)(1,943,775)
Net deferred tax assets4,205 3,615 8,582 
Property, plant and equipment, net(10,795)(12,374)(14,480)
Tax on unremitted earnings(23,735)— — 
Right of use asset(11,682)(7,735)(10,098)
Total gross deferred tax liabilities(46,212)(20,109)(24,578)
Net deferred tax assets/(liabilities)(42,007)(16,494)(15,996)
Schedule of Valuation Allowance
The valuation allowances for the years ended December 31, 2024, 2023 and 2022 were as follows:
 Year Ended December 31,
 202420232022
 
Beginning balance, as of January 12,771,470 1,943,775 1,758,409 
Additions/(subtractions) charged to income tax provision157,286 845,811 229,550 
Additions/(subtractions) charged to equity497,823 — — 
Currency translation and other(23,074)(18,116)(44,184)
Ending balance, as of December 313,403,505 2,771,470 1,943,775 
Schedule of Gross Unrecognized Tax Benefits
The gross unrecognized tax benefits for the years ended December 31, 2024, 2023 and 2022 were as follows:
 Year Ended December 31,
 202420232022
 
Beginning balance, as of January 114,264 11,555 9,925 
Additions based on tax positions related to prior tax years— — — 
Reductions based on tax positions related to prior tax years— — — 
Additions based on tax positions related to the current tax year2,975 2,709 1,630 
Reductions based on lapse of statute of limitations— — — 
Ending balance, as of December 3117,239 14,264 11,555